Dennis M Bierle, Ravindra Ganesh, Sidna Tulledge-Scheitel, Sara N Hanson, Lori L Arndt, Caroline G Wilker, MD Raymund R Razonable
doi:10.1093/infdis/jiab570/6429422
Breakthrough COVID-19 may occur among vaccinated individuals with a high number of medical comorbidities, especially during the SARS-CoV-2 Delta surge. Anti-spike monoclonal antibody treatment was associated with significantly lower rates of hospitalization, particularly among highrisk persons.
Conflict of Interest Statement: Dr. Razonable is principal investigator of research funded by Regeneron, Roche, Gilead (all funds provided to his institution), and is a member of Data Safety Monitoring Board of Novartis, on projects not directly related to this submission. Dr. Razonable received research funds from the Mayo Clinic for studies on monoclonal antibodies for COVID-19. All other no conflict to report.
Results The total population consisted of 1395 fully vaccinated patients (mean age, 54.3 years; 39.6% male) with breakthrough COVID-19 and were screened for monoclonal antibody therapy, under US FDA EUA guidance. The majority of breakthrough SARS-CoV-2 infections (n=1002; 71.8%) occurred during a 6-week period from July 1 to August 16, 2021, when the Delta variant was predominant in our region (Supplemental Figure). The most common medical comorbidities were hypertension (34.5%), cardiovascular disease (13.8%), chronic pulmonary disease (13.6%), and chronic kidney disease (10.2%) (Table 1 ). A total of 170 (12.2%) patients were immunocompromised, including 149 patients (10.7%) with solid cancer and hematologic malignancies and 35 (2.5%) transplant recipients. Most patients (69.8%) received the Pfizer-BioNTech SARS-CoV-2 mRNA vaccine. Breakthrough COVID-19 occurred at median of 124 days (mean, 120 days) after full completion of the vaccination series. At 28 days after breakthrough COVID-19 diagnosis, 107 patients (7.7%) had progressed to require hospitalization...
References
Baden, Sahly, Essink, Efficacy and Safety of the mRNA-1273 SARS-CoV-2
Bergwerk, Gonen, Lustig, Covid-19 Breakthrough Infections in Vaccinated Health Care Workers, N Engl J Med
Bernal, Andrews, Gower, Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant, N Engl J Med
Bierle, Ganesh, Wilker, Influence of Social and Cultural Factors on the Decision to Consent for Monoclonal Antibody Treatment among High-Risk Patients with Mild-Moderate COVID-19, J Prim Care Community Health
Ganesh, Pawlowski, Horo, Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19, J Clin Invest
Ganesh, Philpot, Bierle, Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab among High-Risk Patients with Mild to Moderate Coronavirus Disease 2019, J Infect Dis
Razonable, Aloia, Anderson, A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19: The Mayo Clinic Model, Mayo Clin Proc
Razonable, Pawlowski, Horo, Bierle, Arndt et al., Casirivimab-Imdevimab Treatment is Associated with Reduced Rates of Hospitalization among High-Risk Patients with Mild to Moderate Coronavirus Disease-19, EClinicalMedicine
Swift, Breeher, Tande, Effectiveness of Messenger RNA Coronavirus Disease
Von Elm, Altman, Egger, The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies, Lancet
Weinreich, Sivapalasingam, Norton, COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19, N Engl J Med
Wilhelm, Toptan, Pallas, Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484Q, Viruses
{ 'indexed': { 'date-parts': [[2021, 11, 16]],
'date-time': '2021-11-16T20:44:41Z',
'timestamp': 1637095481009},
'reference-count': 0,
'publisher': 'Oxford University Press (OUP)',
'content-domain': {'domain': [], 'crossmark-restriction': False},
'short-container-title': ['The Journal of Infectious Diseases'],
'DOI': '10.1093/infdis/jiab570',
'type': 'journal-article',
'created': { 'date-parts': [[2021, 11, 12]],
'date-time': '2021-11-12T20:10:14Z',
'timestamp': 1636747814000},
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': ['OUP accepted manuscript'],
'prefix': '10.1093',
'member': '286',
'published-online': {'date-parts': [[2021]]},
'container-title': ['The Journal of Infectious Diseases'],
'original-title': [],
'deposited': { 'date-parts': [[2021, 11, 16]],
'date-time': '2021-11-16T20:11:17Z',
'timestamp': 1637093477000},
'score': 1,
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2021]]},
'references-count': 0,
'URL': 'http://dx.doi.org/10.1093/infdis/jiab570',
'relation': {},
'ISSN': ['0022-1899', '1537-6613'],
'issn-type': [{'value': '0022-1899', 'type': 'print'}, {'value': '1537-6613', 'type': 'electronic'}],
'subject': ['Infectious Diseases', 'Immunology and Allergy'],
'published': {'date-parts': [[2021]]}}
